Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinica trial PHASE I-II of LEDC (Liposomal Encapsulated Doxorubicin Cytrate, Myocet) + CARBOPLATIN IN EPITHELIAL ginecological CANCER [Estudio Fase I-II multicéntrico, abierto, de la combinación de doxorrubicina liposomal encapsulada (Myocet) y carboplatino en el tratamiento de pacientes con cáncer ginecológico o peritoneal primario recurrente].

Trial Profile

Clinica trial PHASE I-II of LEDC (Liposomal Encapsulated Doxorubicin Cytrate, Myocet) + CARBOPLATIN IN EPITHELIAL ginecological CANCER [Estudio Fase I-II multicéntrico, abierto, de la combinación de doxorrubicina liposomal encapsulada (Myocet) y carboplatino en el tratamiento de pacientes con cáncer ginecológico o peritoneal primario recurrente].

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jul 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Doxorubicin liposomal (Primary)
  • Indications Cervical cancer; Endometrial cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2015 Results for the phase I portion in 23 evaluable patients presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2015 The phase I portion has been completed and the phase II portion is in progress, as reported at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 15 Jan 2013 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top